Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
Clinical trial NCT04256980 · COMPLETED
Trial details
- NCT number
- NCT04256980
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-03
- Primary completion
- 2021-01-29
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.